Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis;Anakinra, antagonista umano ricombinante del recettore dell'IL-1, nella pratica clinica. Outcome in 60 pazienti con artrite reumatoide severa

Reumatismo

Volumn 59, Issue 1, 2007, Pages 32-37

  Botsios, Costantino ^a   Sfriso, P ^a   Furlan, A ^a   Ostuni, P ^a   Biscaro, M ^a   Fiocco, U ^a   Todesco, S ^a   Punzi, L ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Adalimumab; Anakinra; Efficacy; Etanercept; Infliximab; Rheumatoid arthritis; Safety

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ISOXAZOLE DERIVATIVE; RECOMBINANT PROTEIN;

ACUTE HEPATITIS; ADULT; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPISCLERITIS; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PNEUMONIA; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; AGED; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34447272928     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lee D, Weinblatt M. Rheumatoid arthritis. Lancet 2001; 358: 903-11.
2. Firestein G, Alvaro-Garcia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347-53.
3. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2004; 43 Suppl 3: iii2-iii9.
4. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996; 14: 397-440.
5. Choy E, Panayi G. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
6. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000; 343: 732-4.
7. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204.
8. Nuki G, Bresnihan B, Bear BM, McCabe D. Long term safety and maintenance of clinical improvement following treatment with anakinra (Recombinant human IL-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 2838-46.
9. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. Amulticenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43: 1001-9.
10. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with Anakinra, a recombinant human IL-1 receptor antagonist, in combination with methotrexate. Results of twenty-four week, multicenter, randomised, double-blind, placebo controlled trial. Arthritis Rheum 2002; 46: 614-24.
11. Fleischmann RM, Schechtman J, Bennett R, Malcolm HL, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (rmetHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48: 927-34.
12. Langer H.E. Missler-Karger B. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol. Int J Clin Pharmacol Res 2003; 23: 119-28.
13. den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH.Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006; 65: 760-2.
14. Konttinen L, Kankaanpaa E, Luosujarvi R Blafield H, Vuori K, Hakala M, et al. Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 2006; 25: 882-4.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
16. Felson DT, Anderson JJ, BoersM, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36: 729-40.
17. Dayer J-M, Bresnihan B. Targeting Interleukin-1 in the treatment of Rheumatoid Arthritis. Arthritis Rheum 2002; 46: 574-8.
18. Finckh A Simard JF Gabay C Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-52.
19. Keystone EC Kavanaugh A. What to do with TNF failures. Expert Opin Drug Saf 2005; 4: 149-55.
20. Botsios C. Safety of tumour necrosis factor and interleukin-1 locking agents in rheumatic diseases. Autoimmun Rev 2005; 4: 162-70.